Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDR701
- Development stage
- Preclinical
- Lead developer
- CDR-Life
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CDR701 is an investigational, antibody-fragment-based T-cell engager (TCE) developed by CDR-Life using its proprietary M-gager® platform. It is designed to target an undisclosed cleaved tumor-associated antigen on solid tumors. By binding to both the cleaved tumor antigen on cancer cells and the CD3 receptor on T cells, CDR701 recruits and activates T cells to selectively eliminate tumor cells while sparing healthy tissues. The program is currently in the discovery/preclinical stage of development for the treatment of solid tumors.
02
Targets
Kita-Kyushu lung cancer antigen 1 peptide-human leukocyte antigen class I complexCD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CDR701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDR701.